Israel Englander Intellia Therapeutics, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 586,489 shares of NTLA stock, worth $6.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

586,489

Previous 668,926 12.32%

Holding current value

$6.37 Million

Previous $7.8 Million 46.54%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$7.11 - $12.8 $586,127 - $1.06 Million	-82,437 Reduced 12.32%	586,489 $4.17 Million
Q4 2024 Feb 14, 2025	BUY	$11.41 - $21.09 $5 Million - $9.25 Million	438,625 Added 190.46%	668,926 $7.8 Million
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $3.05 Million - $4.23 Million	154,627 Added 204.33%	230,301 $4.73 Million
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $2.07 Million - $2.81 Million	-103,205 Reduced 57.7%	75,674 $1.69 Million
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $4.26 Million - $5.87 Million	178,879 New	178,879 $4.92 Million
Q2 2023 Aug 14, 2023	SELL	$34.58 - $46.03 $5.17 Million - $6.88 Million	-149,508 Reduced 49.84%	150,482 $6.14 Million
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $8.32 Million - $11.2 Million	249,869 Added 498.53%	299,990 $11.2 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $9.31 Million - $17.6 Million	-280,321 Reduced 84.83%	50,121 $1.75 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $1.56 Million - $2.08 Million	-28,947 Reduced 8.05%	330,442 $18.5 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $5.42 Million - $10.7 Million	-140,877 Reduced 28.16%	359,389 $18.6 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $28.5 Million - $58.3 Million	489,645 Added 4610.16%	500,266 $36.4 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $9.23 Million - $12.7 Million	-91,646 Reduced 89.61%	10,621 $1.26 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $9.93 Million - $13.3 Million	-74,983 Reduced 42.3%	102,267 $13.7 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $15.4 Million - $40.9 Million	-252,476 Reduced 58.75%	177,250 $28.7 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $4.71 Million - $8.46 Million	101,087 Added 30.76%	429,726 $34.5 Million
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $2.57 Million - $8.66 Million	-136,280 Reduced 29.31%	328,639 $17.9 Million
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $5.74 Million - $8.19 Million	328,494 Added 240.79%	464,919 $9.24 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $1.52 Million - $3.12 Million	136,425 New	136,425 $2.87 Million
Q1 2020 May 14, 2020	SELL	$9.44 - $15.58 $159,300 - $262,912	-16,875 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $30,789 - $52,161	-2,952 Reduced 14.89%	16,875 $248,000
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $2.81 Million - $3.98 Million	-215,190 Reduced 91.56%	19,827 $264,000
Q2 2019 Aug 15, 2019	SELL	$13.88 - $18.41 $79.9 Million - $106 Million	-5,757,263 Reduced 96.08%	235,017 $3.85 Million
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $82.4 Million - $109 Million	5,937,362 Added 10811.32%	5,992,280 $69 Million
Q1 2019 May 14, 2019	SELL	$12.79 - $17.62 $18,379 - $25,319	-1,437 Reduced 2.55%	54,918 $938,000
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $641,883 - $1.53 Million	56,355 New	56,355 $769,000
Q1 2018 May 15, 2018	SELL	$19.43 - $34.95 $690,600 - $1.24 Million	-35,543 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $618,092 - $1.11 Million	35,543	35,543 $683,000

Others Institutions Holding NTLA

# of Institutions

341

Shares Held

95.7M

Call Options Held

1.29M

Put Options Held

1.09M

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $825M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account